Nexstim

8.2

EUR

-4.65 %

Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

5,297 following

-4.65%

+62.06%

+121.62%

+176.09%

+178.91%

+233.33%

+82.63%

+250.98%

-98.65%

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Market cap

58.73M EUR

Turnover

221.47K EUR

P/E (adj.) (24e)

-606.37

EV/EBIT (adj.) (24e)

18,722.76

P/B (24e)

15.57

EV/S (24e)

6.47

Dividend yield-% (24e)

-

Coverage

Recommendation

Accumulate

Target price

6.20 EUR

Updated

02.12.2024

Latest research

Latest analysis report

Released: 02.12.2024

Latest extensive report

Released: 06.10.2023

Financial calendar

27.2

2025

Annual report '24

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Press releaseyesterday

Delve Psychiatry in Nevada, United States Orders Nexstim NBS 5+ System

Press release12/19/2024, 8:00 AM

Nexstim Receives NBS 6 Order from University Hospital in California

Press release12/18/2024, 7:00 AM

Distributor Orders Two Nexstim NBS 5 Systems

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release12/17/2024, 7:00 AM

Finnish University Hospital Orders Nexstim NBS System 5

Press release12/16/2024, 7:00 AM

Nexstim Receives an Upgrade Order from a German University Hospital

Press release12/13/2024, 7:00 AM

US Customer Orders Nexstim NBS System 5

Regulatory press release12/5/2024, 8:00 AM

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Regulatory press release12/3/2024, 12:45 PM

Nexstim Plc: Managers’ Transactions, Forss

Regulatory press release12/2/2024, 2:30 PM

Nexstim Plc: Managers’ Transactions, Niemistö

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Regulatory press release12/2/2024, 10:30 AM

Nexstim Plc: Managers’ Transactions, Weckroth

Research12/2/2024, 8:36 AM by

Nexstim: Further evidence of cash flow turnaround

Nexstim's year of surprises continued on Friday when the company announced a new development and distribution cooperation agreement with Germany's Brainlab AG. The agreement will strengthen Nexstim's financial position and improve its performance starting next year.

Regulatory press release11/29/2024, 12:05 PM

The Board of Directors of Nexstim Plc has decided on a directed share issue and issuance of special rights to Brainlab AG and on the conversion of a convertible bond

Regulatory press release11/29/2024, 7:15 AM

Inside Information: Nexstim Plc and Brainlab AG initiate collaboration by signing development and distributorship cooperation agreement and agreeing on a maximum of EUR 5,095,000 equity investment into Nexstim

Press release11/19/2024, 1:00 PM

New German Customer Orders Nexstim NBS System 5

Press release11/15/2024, 1:00 PM

Nexstim Receives System Order from University Hospital in United States

Press release11/4/2024, 7:30 AM

New Finnish Customer Orders Two Nexstim NBS 6 Systems

Business news update from Nexstim

Analyst Comment10/31/2024, 7:03 AM by

Business news update from Nexstim

Nexstim issued a press release on business highlights for January-September. The company said it has invested in profitable growth, development of its NBS 6 diagnostics product and expansion of its network of clinics.

Press release10/30/2024, 7:00 AM

Nexstim Plc Business Update Q3 2024

Research10/21/2024, 6:07 AM by

Nexstim: Taking a breather after handsome returns

On Friday, Nexstim announced that it had obtained a license in India, which means an authorization to sell the NBS5 system in a new market. We raised our medium- and long-term forecasts based on the new market opening, although the visibility of the Indian market is very limited.

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.